Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-2261 in refractory chronic cough
NCT05733533Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-2261 in refractory chronic cough (RCC), sponsored by Hengrui Therapeutics. Started Mar 2023; status: completed.
02
Drugs
HRS-2261
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT05733533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05733533.